ArticleWorld journal of surgical oncology2015
Is revisional surgery mandatory when an unexpected sarcoma diagnosis is made following primary surgery?
Article in World journal of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- Is delayed three-month re-excision safe for patients who have undergone unplanned excision of soft tissue sarcomas?Journal of orthopaedic surgery and research · 2026Article
- Proton Beam Therapy and the AYA Sarcoma Patient Journey: Highlighting Needs from Diagnosis to Survivorship.Cancers · 2025Review
- Unplanned Excision in Soft Tissue Sarcoma: Current Knowledge and Remaining Gaps.Diagnostics (Basel, Switzerland) · 2025Review
- Early Complications of Planned Resection Versus Unplanned Excision of Sarcomas in the Distal Upper Extremity.Journal of hand surgery global online · 2024Article
- Review
- Review
- Impact of the unplanned excision on the oncological outcomes of patients with soft tissue sarcomas: a single-center retrospective review of 490 patients.Acta orthopaedica et traumatologica turcica · 2022Article
- Definition of the Surgical Case Complexity in the Treatment of Soft Tissue Tumors of the Extremities and Trunk.Cancers · 2022Article
- Accuracy of core needle biopsy for histologic diagnosis of soft tissue sarcoma.Scientific reports · 2022Article
- Nanomaterial Technology and Soft Tissue Sarcomas.Frontiers in oncology · 2022Review
- Unplanned excision of soft tissue sarcoma: does it impact the accuracy of intra-operative pathologic assessment at time of re-excision?International orthopaedics · 2021Article
- Identification of uterine leiomyosarcoma-associated hub genes and immune cell infiltration pattern using weighted co-expression network analysis and CIBERSORT algorithm.World journal of surgical oncology · 2021Article
- Dermatofibrosarcoma protuberans in a young patient with epidermolysis bullosa: a case report.BMC surgery · 2021Article
- Rationale for Early Detection ofCancers · 2021Review
- Epithelioid Sarcoma in a Young Child: A Case Report and Literature Review.Plastic and reconstructive surgery. Global open · 2021Article
- Efficacy and Cost-Benefit Analysis of Magnetic Resonance Imaging in the Follow-Up of Soft Tissue Sarcomas of the Extremities and Trunk.Journal of oncology · 2021Article
- Locally recurrent extraskeletal myxoid chondrosarcoma of the shoulder: a case of complete neoadjuvant radiotherapy response.Clinical sarcoma research · 2020Article
- Achilles tendon reconstruction with peroneus tendon transfer following epithelioid sarcoma resection: a rare case report at 5 years follow-up.Journal of experimental orthopaedics · 2020Article
- Inadvertent excision of malignant soft tissue tumours.EFORT open reviews · 2019Review
- Soft Tissue Sarcoma of the Hand and Wrist: Epidemiology and Management Challenges.Journal of hand and microsurgery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSoft tissue sarcomas (STS) are often diagnosed unexpectedly after surgery, and many excisions are incomplete. As histopathological assessments are challenging, patients later referred to comprehensive cancer centers (CCC) often come with an unclear status. This can make treatment planning problematic. We investigated the reliability of primary histopathological assessments, whether revisional surgery improved resection status, and the prognostic value of residual tumor at re-excision.
methodsWe analyzed the demographic and clinical characteristics of all patients referred to our CCC between 2003 and 2013. We compared patients treated exclusively at our CCC with those who had primary surgery elsewhere, and focused on resection margins, re-excision type, residual tumor, resection status after re-excision, and oncological outcome.
resultsOver half (n = 110) of all patients (n = 204) were referred from elsewhere. Seventy-one had undergone an excision without suspicion of malignancy. Resection status in referred patients was significantly inferior to the CCC group (p < 0.0001), although the latter had significantly more serious tumors and advanced disease stages (p < 0.05). The residual tumor rate was 53.13%, with a significantly higher probability in an upper extremity (p = 0.001). Initial histopathological classification was misleading in 46.9% of cases. Re-excision improved resection status in 69% of cases. Residual tumor presumably leads to higher rates of local recurrence (p = 0.057) and significantly shorter times to recurrence (p < 0.05).
conclusionsRe-excision should always follow unplanned STS excisions. Resection margins and histopathological assessments from referring institutions are often unreliable and unsuitable for treatment planning. Residual tumor is a risk factor for earlier and more likely local recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.